Continuous glucose monitoring–guided management of capivasertib‐associated hyperglycemia: A case series of three patients

Journal of Diabetes Investigation 2026 Open access

Read full text
Authors: Hiroki Okumura, Ryotaro Bouchi, Kenju Ando, Hannah Mizuno, Hirofumi Sugimoto, Kotaro Umamoto, Noriko Kodani, Noriko Ihana‐Sugiyama, Kazuo Izumi, Mitsuru Ohsugi, Kohjiro Ueki, A. Shimomura
+2 more Chikako Shimizu, Akiyo Tanabe
DOI: 10.1111/jdi.70342
Cited by: 1
References: 9

Abstract

Capivasertib, an AKT inhibitor for advanced breast cancer, frequently induces hyperglycemia. We present a case series of three patients (two without pre-existing diabetes) monitored with continuous glucose monitoring. Hyperglycemia developed within 2 weeks in all cases. Continuous glucose monitoring visualized glycemic fluctuations synchronized with the "4-days-on, 3-days-off" cycle. A patient with low baseline homeostatic model assessment for β-cell function and higher insulin resistance required insulin, whereas a patient with relatively preserved insulin action was managed with oral glucose-lowering agents. These hypothesis-generating observations suggest that pretreatment metabolic assessment might assist in preliminary risk stratification.

Fields of Study & Subjects

Advanced Breast Cancer Therapies PI3K/AKT/mTOR signaling in cancer Metabolism Diabetes and Cancer

Publication details

Journal / source
Journal of Diabetes Investigation
Publisher
Wiley
Volume
17
Issue
8
Pages
1432–1437
Publication date
19 May 2026
Language
EN